** Shares of drug developer Biohaven BHVN.N fall 1.6% to $29.92
** Brokerage Morgan Stanley cuts PT on BHVN to $63 from $69, after co's experimental bipolar disorder drug failed in a study
** Co on Monday said the drug, BHV-7000, did not show statistical improvement in symptoms of extreme mood swings in a mid-to-late stage trial when measured on a scale
** Brokerage now anticipates 2035 sales of $1.4 bln for the drug vs. $1.5 bln prior, which includes potential treatment for neurological diseases like different types of epilepsy and major depressive disorder
** Adds primary focus for the stock to remain on U.S. FDA's decision on brain disorder drug troriluzole this summer
** Brokerage maintains "overweight" rating; new PT is more than double upside to the stock's last close on Thursday
** BHVN has fallen 47.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.